Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study

AIMS/INTRODUCTION: Liraglutide and empagliflozin suppress cardiovascular events. However, reports on their long‐term combined use with insulin therapy or direct comparisons of these drugs are limited. MATERIALS AND METHODS: This open‐label, parallel‐group, randomized controlled trial compared the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaguchi, Hirotatsu, Kondo, Yoshinobu, Kyohara, Mayu, Konishi, Hiromi, Oiwa, Koji, Terauchi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610130/
https://www.ncbi.nlm.nih.gov/pubmed/32279451
http://dx.doi.org/10.1111/jdi.13270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610130/
https://www.ncbi.nlm.nih.gov/pubmed/32279451
http://dx.doi.org/10.1111/jdi.13270

Ejemplares similares